Slattery S A, Niaz O, Aziz Q, Ford A C, Farmer A D
Neurogastroenterology Group, Blizard Institute of Cell & Molecular Science, Wingate Institute of Neurogastroenterology, Barts & the London School of Medicine & Dentistry, Queen Mary University of London, London, UK.
Blackpool Victoria Hospital, Blackpool, UK.
Aliment Pharmacol Ther. 2015 Jul;42(1):3-11. doi: 10.1111/apt.13227. Epub 2015 Apr 27.
Irritable bowel syndrome is a widespread disorder with a marked socioeconomic burden. Previous studies support the proposal that a subset of patients with features compatible with diarrhoea-predominant IBS (IBS-D) have bile acid malabsorption (BAM).
To perform a systematic review and meta-analysis to assess the prevalence of BAM in patients meeting the accepted criteria for IBS-D.
MEDLINE and EMBASE were searched up to March 2015. Studies recruiting adults with IBS-D, defined by the Manning, Kruis, Rome I, II or III criteria and which used 23-seleno-25-homotaurocholic acid (SeHCAT) testing for the assessment of BAM were included. BAM was defined as 7 day SeHCAT retention of <10%. We calculated the rate of BAM and 95% confidence intervals (CI) using a random effects model. The methodological quality of included studies was evaluated using the Quality Assessment for Diagnostic Accuracy Studies (QUADAS-2).
The search strategy identified six relevant studies comprising 908 individuals. The rate of BAM ranged from 16.9% to 35.3%. The pooled rate was 28.1% (95% CI: 22.6-34%). There was significant heterogeneity in effect sizes (Q-test χ(2) = 17.9, P < 0.004; I(2) = 72.1%). The type of diagnostic criteria used or study country did not significantly modify the effect.
These data provide evidence that in excess of one quarter of patients meeting accepted criteria for IBS-D have bile acid malabsorption. This distinction has implications for the interpretation of previous studies, as well as contemporaneous clinical practice and future guideline development.
肠易激综合征是一种广泛存在的疾病,具有显著的社会经济负担。先前的研究支持这样一种观点,即一部分具有腹泻型肠易激综合征(IBS-D)特征的患者存在胆汁酸吸收不良(BAM)。
进行一项系统评价和荟萃分析,以评估符合IBS-D公认标准的患者中BAM的患病率。
检索截至2015年3月的MEDLINE和EMBASE数据库。纳入招募符合曼宁、克鲁伊斯、罗马I、II或III标准定义的IBS-D成年患者且使用23-硒-25-高牛磺胆酸(SeHCAT)检测评估BAM的研究。BAM定义为7天SeHCAT潴留率<10%。我们使用随机效应模型计算BAM的发生率和95%置信区间(CI)。使用诊断准确性研究质量评估(QUADAS-2)对纳入研究的方法学质量进行评估。
检索策略确定了6项相关研究,共908例个体。BAM的发生率在16.9%至35.3%之间。合并发生率为28.1%(95%CI:22.6 - 34%)。效应大小存在显著异质性(Q检验χ(2)=17.9,P<0.004;I(2)=72.1%)。所用诊断标准的类型或研究国家对效应无显著影响。
这些数据表明,超过四分之一符合IBS-D公认标准的患者存在胆汁酸吸收不良。这一区别对既往研究的解读、当前临床实践及未来指南的制定均有影响。